- Home
- ROIV vs UMBF Comparison
ROIV vs UMBF Comparison
Compare ROIV & UMBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- UMBF
- Stock Information
- Founded
- ROIV 2014
- UMBF 1913
- Country
- ROIV United Kingdom
- UMBF United States
- Employees
- ROIV N/A
- UMBF N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- UMBF Major Banks
- Sector
- ROIV Health Care
- UMBF Finance
- Exchange
- ROIV Nasdaq
- UMBF Nasdaq
- Market Cap
- ROIV 8.6B
- UMBF 8.7B
- IPO Year
- ROIV N/A
- UMBF N/A
- Fundamental
- Price
- ROIV $12.92
- UMBF $124.47
- Analyst Decision
- ROIV Strong Buy
- UMBF Buy
- Analyst Count
- ROIV 4
- UMBF 9
- Target Price
- ROIV $15.50
- UMBF $133.22
- AVG Volume (30 Days)
- ROIV 5.2M
- UMBF 483.5K
- Earning Date
- ROIV 08-11-2025
- UMBF 10-28-2025
- Dividend Yield
- ROIV N/A
- UMBF 1.29%
- EPS Growth
- ROIV N/A
- UMBF 12.71
- EPS
- ROIV N/A
- UMBF 8.74
- Revenue
- ROIV $23,233,000.00
- UMBF $1,949,350,000.00
- Revenue This Year
- ROIV N/A
- UMBF $67.29
- Revenue Next Year
- ROIV $281.14
- UMBF $7.70
- P/E Ratio
- ROIV N/A
- UMBF $14.15
- Revenue Growth
- ROIV N/A
- UMBF 31.18
- 52 Week Low
- ROIV $8.73
- UMBF $82.00
- 52 Week High
- ROIV $13.08
- UMBF $129.94
- Technical
- Relative Strength Index (RSI)
- ROIV 73.31
- UMBF 72.27
- Support Level
- ROIV $11.85
- UMBF $119.33
- Resistance Level
- ROIV $13.08
- UMBF $124.20
- Average True Range (ATR)
- ROIV 0.31
- UMBF 2.81
- MACD
- ROIV 0.10
- UMBF 0.27
- Stochastic Oscillator
- ROIV 89.61
- UMBF 90.01
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About UMBF UMB Financial Corporation
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.